In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal Moves Downstream in Drug Wholesaling

Executive Summary

Through a series of innovative service acquisitions, Cardinal is moving closer to the point of dispensing and to the point where it can influence product selection.

You may also be interested in...



In Hospital Supply, Signs of an M&A Renaissance?

Cardinal Health's acquisition of IV-pump specialist Alaris Medical Systems certainly came as no surprise. The company had been reportedly on the blocks for years. But the fact that Alaris fetched few takers was, certainly on some level, a reflection of the depressed prospects for hospital supply companies and, in turn, for M&A activity. Joining forces with Cardinal brings Alaris into the broader context of a bundled offering, and in the process, also reaffirms the value inherent in today's hospital supply marketplace. Teleflex's acquisition of Hudson Respiratory Care for $460 million marks a potentially more interesting deal. Teleflex officials have been looking for years for new properties to acquire, as part of a broader effort to build up and around their core businesses in wound closure and surgical instruments. The two deals taken together--Cardinal's acquisition of Alaris and Teleflex's of Hudson--suggest that deal-making in hospital supply is far from dead and may, in the future, be done from a business-building, rather than a business-fleeing posture.

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel